Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127977621 | 12797762 | 1 | I | 20160823 | 20160930 | 20160930 | EXP | US-ROCHE-1835388 | ROCHE | 59.00 | YR | F | Y | 118.30000 | KG | 20160930 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127977621 | 12797762 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | OVER 30-90 MINUTES ON DAY 1?COURSE ID 1?LAST TREATMENT DATE: 05/SEP/2012 | U | 125085 | |||||||||
| 127977621 | 12797762 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID 2 | U | 125085 | 1660 | MG | |||||||
| 127977621 | 12797762 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID 3 | U | 125085 | 1660 | MG | |||||||
| 127977621 | 12797762 | 4 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID 4 | U | 125085 | 1660 | MG | |||||||
| 127977621 | 12797762 | 5 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID 5 | U | 125085 | 1660 | MG | |||||||
| 127977621 | 12797762 | 6 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID 6 | U | 125085 | 1660 | MG | |||||||
| 127977621 | 12797762 | 7 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID 7 | U | 125085 | 1660 | MG | |||||||
| 127977621 | 12797762 | 8 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID 8 | U | 125085 | 1660 | MG | |||||||
| 127977621 | 12797762 | 9 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID 9 | U | 125085 | 1660 | MG | |||||||
| 127977621 | 12797762 | 10 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID 10 | U | 125085 | 1660 | MG | |||||||
| 127977621 | 12797762 | 11 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID 11 | U | 125085 | 1660 | MG | |||||||
| 127977621 | 12797762 | 12 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID 12 | U | 125085 | 1660 | MG | |||||||
| 127977621 | 12797762 | 13 | SS | IXABEPILONE | IXABEPILONE | 1 | Intravenous (not otherwise specified) | OVER 1 HOUR?COURSE ID 1?LAST TREATMENT DATE: 05/SEP/2012 | U | 0 | 52.5 | MG | |||||||
| 127977621 | 12797762 | 14 | SS | IXABEPILONE | IXABEPILONE | 1 | Intravenous (not otherwise specified) | COURSE ID 2 | U | 0 | 53 | MG | |||||||
| 127977621 | 12797762 | 15 | SS | IXABEPILONE | IXABEPILONE | 1 | Intravenous (not otherwise specified) | COURSE ID 3 | U | 0 | 53 | MG | |||||||
| 127977621 | 12797762 | 16 | SS | IXABEPILONE | IXABEPILONE | 1 | Intravenous (not otherwise specified) | COURSE ID 4 | U | 0 | 53.3 | MG | |||||||
| 127977621 | 12797762 | 17 | SS | IXABEPILONE | IXABEPILONE | 1 | Intravenous (not otherwise specified) | COURSE ID 5 | U | 0 | 53.3 | MG | |||||||
| 127977621 | 12797762 | 18 | SS | IXABEPILONE | IXABEPILONE | 1 | Intravenous (not otherwise specified) | COURSE ID 6 | U | 0 | 53 | MG | |||||||
| 127977621 | 12797762 | 19 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | OVER 30 MINUTES | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127977621 | 12797762 | 1 | Endometrial cancer |
| 127977621 | 12797762 | 13 | Endometrial cancer |
| 127977621 | 12797762 | 19 | Endometrial cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127977621 | 12797762 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127977621 | 12797762 | Abdominal pain | |
| 127977621 | 12797762 | Arthralgia | |
| 127977621 | 12797762 | Back pain | |
| 127977621 | 12797762 | Bone pain | |
| 127977621 | 12797762 | Headache | |
| 127977621 | 12797762 | Hypertension | |
| 127977621 | 12797762 | Hypoacusis | |
| 127977621 | 12797762 | Hypothyroidism | |
| 127977621 | 12797762 | Neck pain | |
| 127977621 | 12797762 | Oedema peripheral | |
| 127977621 | 12797762 | Pain | |
| 127977621 | 12797762 | Pulmonary haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127977621 | 12797762 | 1 | 20111206 | 0 | ||
| 127977621 | 12797762 | 2 | 20111228 | 0 | ||
| 127977621 | 12797762 | 3 | 20120117 | 0 | ||
| 127977621 | 12797762 | 4 | 20120207 | 0 | ||
| 127977621 | 12797762 | 5 | 20120228 | 0 | ||
| 127977621 | 12797762 | 6 | 20120320 | 0 | ||
| 127977621 | 12797762 | 7 | 20120410 | 0 | ||
| 127977621 | 12797762 | 8 | 20120502 | 0 | ||
| 127977621 | 12797762 | 9 | 20120523 | 0 | ||
| 127977621 | 12797762 | 10 | 20120612 | 0 | ||
| 127977621 | 12797762 | 11 | 20120807 | 0 | ||
| 127977621 | 12797762 | 12 | 20120905 | 0 | ||
| 127977621 | 12797762 | 13 | 20111206 | 0 | ||
| 127977621 | 12797762 | 14 | 20111228 | 0 | ||
| 127977621 | 12797762 | 15 | 20120117 | 0 | ||
| 127977621 | 12797762 | 16 | 20120207 | 0 | ||
| 127977621 | 12797762 | 17 | 20120228 | 0 | ||
| 127977621 | 12797762 | 18 | 20120320 | 0 |